Arvinas, Inc (ARVN)
PHARMACEUTICAL PREPARATIONS
Arvinas, Inc (ARVN) is listed on Nasdaq, where it has traded since September 27, 2018.
- Listed On
- Nasdaq
- Listed Since
- September 27, 2018
- Employees
- 246
- Market Cap
- $497M
About Arvinas, Inc
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 192 institutions reported holding ARVN, with 55.4 million shares worth $467.0 million in aggregate. The largest reported holder was BlackRock, with 7.6 million shares worth $63.2 million. Of the 5 largest holders listed below, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| BlackRock | 7,609,123 | $63M | Added 11.94% |
| Vanguard | 7,339,943 | $61M | Added 3.81% |
| D. E. Shaw | 3,495,153 | $29M | Reduced 3.94% |
| Pfizer | 3,457,815 | $28M | Unchanged |
| Armistice Capital | 2,796,000 | $23M | Added 41.35% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is ARVN?
Arvinas, Inc (ARVN) is listed on Nasdaq, where it has traded since September 27, 2018.
Who are the largest institutional holders of ARVN?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of ARVN were BlackRock, Vanguard and D. E. Shaw.
How many institutions own ARVN?
192 institutions reported a position in ARVN for the quarter ended June 30, 2026, worth $467.0 million in total.
Did institutions buy or sell ARVN last quarter?
Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for ARVN.
Every reported institutional holder, plus insider and congressional trades in ARVN, on SentiSense.